EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 45 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC MOST POPULAR Want to learn more about Sulforaphanes? December 4, 2020 Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma September 29, 2022 Making Important Decisions During Cancer: A Survivor’s Story October 26, 2021 Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer June 4, 2020 Load more HOT NEWS Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in... How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... Prostate Cancer Genomics in Racial Minority Groups The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce
